← Back to Clinical Trials
Recruiting NCT06907810

NCT06907810 Study of Lipid Mediators in Chronic Postoperative Pain - LICP

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06907810
Status Recruiting
Phase
Sponsor Université Catholique de Louvain
Condition Breast Cancer Female
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2025-03-12
Primary Completion 2027-03-31

Trial Parameters

Condition Breast Cancer Female
Sponsor Université Catholique de Louvain
Study Type INTERVENTIONAL
Phase N/A
Enrollment 300
Sex FEMALE
Min Age 18 Years
Max Age N/A
Start Date 2025-03-12
Completion 2027-03-31
Interventions
Blood sample + questionnaire

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This interventional prospective study aims firstly to investigate variations in lipid levels in blood samples and their potential relationship with the duration and/or intensity of post-operative pain. Secondly, it aims to investigate the activation of peripheral blood mononuclear cells and neutrophils in patient blood samples. The study will enrol women aged 18 years or older who have been newly diagnosed with primary invasive or non-invasive breast cancer requiring surgical removal of the tumour, with or without axillary surgery. The main objectives of the study are To assess whether there is an association between circulating levels of lipid mediators and chronicity (\> 3 months) of postoperative pain after breast cancer surgery. To assess whether circulating levels of lipid mediators can predict chronicity of postoperative pain in breast cancer surgery. To assess the existence of an association between resected tissue levels of lipid mediators and chronicity of postoperative pain in breast cancer surgery. To assess whether tissue levels of lipid mediators can predict chronicity of postoperative pain in breast cancer surgery.

Eligibility Criteria

Inclusion Criteria: * Women older than 18 years * Newly diagnosed primary invasive or non-invasive breast cancer, requiring surgical excision of the tumor, with or without axillary surgery * Able to give informed consent Exclusion Criteria: * Men * Women aged less than 18 years * Pregnant women * History of major psychiatric disorders * Previous breast or axillary surgery, recurrent disease or detectable metastatic disease at the time of diagnosis * Unable to give informed consent

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology